Skip to main content
Premium Trial:

Request an Annual Quote

GNS to Provide CombinatoRx with Modeling Software for Drug Studies

NEW YORK (GenomeWeb News) - Gene Network Sciences will use its biological modeling software to assist CombinatoRx in drug efficacy and safety studies, GNS said last week.
 
Under the agreement, the companies will use GNS' reverse engineering/forward simulation software, which it calls REFSTM, to characterize the cellular mechanisms that can cause “synergistic interactions” between multi-target candidate drugs.
 
REFSTM will use data from CombinatoRx’s protein expression and transcriptional profiling studies to create models that simulate both the mechanisms of disease and clinical performance in drug candidates, GNS said.
 
Financial terms of the agreement were not released.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.